Partnering opportunity

New biomarkers and technologies for circulating tumor cells (CTC) identification and isolation


A Spanish research group of the public health system has developed a new technology for improving circulating tumor cells (CTCs) isolation, detection and characterization. A license agreement or an agreement for a public or private partnership for the further development of the patented technology is sought.

Partner sought

The research team wants to collaborate with researchers, companies and foundations that are interested in adapting chemical tools to biological and therapeutic applications. The research team is looking for license agreements or an agreement for public or private partnership for the development of technology.


Metastasis is responsible for the vast majority of cancer-related deaths. During this process, circulating tumour cells (CTCs) are generated, spread from the primary tumour, colonize distant organs and lead to overt metastatic disease. During the past decade a growing interest in CTCs has spread out across the oncology field, especially looking at their capacity as prognostic elements of cancer. Despite important progresses in understanding and detecting CTCs, most of the assays still have low sensitivity; mainly due to the use of a few epithelial biomarkers to identify and isolate them from whole blood. A Spanish hospital research group has designed a procedure to detect circulating tumor cells (CTCs), both circulating tumor cells of phenotype epithelial as circulating tumor cells that present Epithelial-Mesenchymal Transition (EMT) markers using miRNA-21 as a biomarker. The research group is looking for the following collaboration: -License agreement: framework of authorizing the interested parts to use the technology. -Technical cooperation agreement: to collaborate with other research teams, companies or foundations to adapt the technologies to biological and therapeutic applications.

Advantages and innovations

- The heterogeneity present in the CTCs implies the existence of different subpopulations that cannot be isolated and detected with the mere use of epithelial markers. - The new procedure developed will allow the incorporation of mesenchymal markers to the isolation and detection devices of CTCs that will allow the identification of these subpopulations of CTCs with characteristics of mesenchymal cells. - The identification of these subpopulations will also allow the selection of therapies directed against tumor cells of epithelial origin that present these mesenchymal or semi mesenchymal phenotypes, in a more individualized and more specific way. - New group of CTC's epithelial biomarkers for prognosticating cancer. More specifically: colon cancer, lung cancer, breast cancer (non-metastatic breast cancer) and prostate cancer.

Development stage

Available for demonstration

Intellectual Property Rights (IPR)

Patent(s) applied for but not yet granted

Register your interest

How it works

  • Tell us about yourself
  • We’ll discuss with you
  • We put the right partners in touch

EEN help you find the right partner, rather than you going it alone.

Our role is to review and collate the most suitable submissions, and then send them to the client who posted the opportunity. We consult with you, and the client, to make the process professional and easy.

These are live opportunities. Your registration of interest on the site is just like a professional approach to a business at a networking event. To stand the best chance of success, make your submission really sing. Sell why the client who posted the opportunity should work with you. Excite them. Ask questions. Try and avoid copy and pasting words from elsewhere.

Once the client has chosen their partner, we'll introduce them over email and keep in touch with both parties to see how it's going. Sometimes things progress quickly. Sometimes because of changing priorities for either party, things progress slowly, but you never know - your next big business break could start right here.

?What value does EEN add?
This is your pitch: remember to include your unique selling points (USP) and why someone would want to do business with you
Tell us why you are a good fit for this opportunity, and why you think you're the right people for this partnership
If there's anything additional, or commercially sensitive you'd like to know about this opportunity, please let us know

When you entered your email address above, we emailed you a code to verify you're human and have access to that account.

?What's this?

What next?

To finish up, we just need some extra details about you and your company